Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

*
(*) mandatory field





 

Other search option(s)

Wolf-Hirschhorn syndrome

Orpha number ORPHA280
Synonym(s) 4p- syndrome
Distal deletion 4p
Distal monosomy 4p
Telomeric deletion 4p
Prevalence 1-9 / 100 000
Inheritance
  • Sporadic
Age of onset Neonatal/infancy
ICD-10
  • Q93.3
OMIM
UMLS
  • C1956097
MeSH
  • C536740
  • D054877
MedDRA
  • 10050361
SNOMED CT
  • 17122004

Summary

Wolf-Hirschhorn syndrome (WHS) is a developmental disorder characterized by typical craniofacial features, prenatal and postnatal growth impairment, intellectual disability, severe delayed psychomotor development, seizures, and hypotonia.

The disease has an estimated prevalence of 1:50,000 births.

WHS occurs more frequently in females than in males (2:1). Marked intra-uterine growth retardation and ongoing postnatal slow weight gain are observed. Patients have a distinctive facies characterized by the ''Greek warrior helmet'' appearance (broad nasal bridge continuing to the forehead), visible more clearly before puberty, microcephaly, high forehead with prominent glabella, hypertelorism, epicanthus, highly arched eyebrows, short filtrum, downturned mouth, micrognathia, poorly formed ears with pits/tags and, in some cases, cleft lip/palate. Skeletal anomalies include kyphosis or scoliosis with malformed vertebral bodies, accessory or fused ribs, clubfeet and split hand. Patients suffer from hypotonia with muscle underdevelopment, possibly causing frequent feeding difficulties and may lead to failure to thrive. Developmental delay is severe: most patients do not achieve sphincter control, self-feeding or dressing, and less than 50% walk, with or without support, between 2 and 12 years of age. Intellectual deficit is moderate to severe, rarely mild. Speech is limited to guttural or disyllabic sounds, except in a few patients achieving formulation of simple sentences. Various types of seizures are observed in up to 95%, onset is between the neonatal period and 36 months and the triggering factor is often fever. Status epilepticus occurs in half of patients. Over 30% of children develop atypical absences by age 1 to 6. In approximately 50%, seizures stop in childhood. Most patients have structural central nervous system defects, mainly including thinning of the corpus callosum. Congenital heart defects, and mostly atrial septal defect, are seen in 50%. Ophtalmologic, auditory and dental anomalies are also frequently observed. Patients may have recurrent respiratory tract infections and otitis media, due to antibodies deficiency (Ig1 or IgG2 subclass). Urinary tract malformations have been described, and half of male patients have hypospadias and cryptorchidism.

WHS is due to a deletion in the short arm of the 4th chromosome (4p16.3 region), including at least part of the LETM1 and WHSC1 genes. Deletions greater than 3 Mb seem to be associated with higher risk of heart defects and cleft palate.

Diagnosis is based on physical examination and confirmed by molecular genetics or cytogenetic analysis, fluorescence in situ hybridization (FISH), and genome-wide chromosomal microarray analysis (CMA) being the methods of choice. Electroencephalographic (EEG) investigations show typical findings in 90% of patients.

Differential diagnosis includes many syndromes displaying growth failure, intellectual disability and/or facial dysmorphism such as Seckel, CHARGE, Smith-Lemli-Opitz, Opitz G/BBB, Williams, Rett, Angelman and Smith-Magenis syndromes (see these terms).

Antenatal testing is feasible when a 4p16.3 chromosome rearrangement is already identified in one parent.

Most cases are sporadic, but an unbalanced translocation may be inherited from a parent with a balanced rearrangement.

Treatment is symptomatic and requires multidisciplinary management including diverse rehabilitation programs, seizure treatment (valproic acid with or without ethosuccimide) and feeding therapies.

WHS patients survive into adult life.

Expert reviewer(s)

  • Dr Agatino BATTAGLIA

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.


Captcha image

Detailed information

Summary information
Clinical practice guidelines
  • ES (2010,pdf)
Guidance for genetic testing
  • EN (2010,pdf)
Clinical genetics review
  • EN (2010)
Get Acrobat Reader
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.